News
Quarantine stocks of lidocaine ‘delay spray’, MHRA tells retailers
In News
Bookmark
Record learning outcomes
The MHRA has announced a recall of a lidocaine spray marketed to men as a product to help delay ejaculation after the manufacturer came forward.
Leeds Trading Company, which trades as LTC healthcare, informed the medicines regulator that it has been selling EXS Delay Spray Plus without MHRA authorisation.
“There is limited information on the quantity of lidocaine present in EXS Delay Spray Plus, therefore as a precautionary measure the product is being recalled on safety grounds, noting the product has not undergone the appropriate assessments related to safety, quality and efficacy,” said the MHRA.
“The company’s investigation is ongoing and all remaining stock of the product should be returned to the company directly.”
The recall affects two product batches, one first distributed in November 2023 and the other in April 2024. Patients are advised to stop using the product immediately, while health professionals, wholesalers and retailers have been told to cease supply and quarantine remaining stock before liaising with the manufacturer to arrange returns.
LTC healthcare has been approached for comment.